Related Experiment Video
Updated: Jan 25, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
[Are there different responses to different PCSK9 inhibitors?]
Á Asenjo Mota1, O Caamaño Selma1, R Sánchez-Aquino González2
1Medicina Interna, Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, España.
Abstract:
The case is presented of a 62-year-old patient who required lipid-lowering therapy with proprotein convertase subtilisin/kexin type9 (PCSK9). It was empirically decided to change one drug to another of the two currently available, obtaining a different response. Our objective is to present our experience and to consider a possible therapeutic option in patients in whom, exceptionally, this could happen.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Dipeptidyl Peptidase 4 Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Responses to Gravity and Touch
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

